Mr. D. Thomas Oakley

• 
  www.bridgecro.com/readarticle.php?id=1 - [Cached Version]
  Published on: 7/9/2008    Last Visited: 8/16/2008  

  "IP culture has changed significantly in the past few years, and policies are coming into place," D. Thomas Oakley, CEO of Bridge Laboratories, said of an issue that has plagued China from day one.
  
  However, it will not be smooth sailing from here on and the sector should not rest on its laurels.According to Oakley, China is lacking toxicology scientists, which will one day act as a bottleneck to R & D process.In addition, he said that China's R & D boom may mean that the country's abundant animal resources may face a shortage.

• 
  www.citybizlist.com/lstg/lstgDetail.aspx?id=22671 - [Cached Version]
  Published on: 7/30/2007    Last Visited: 9/2/2007  

  Bridge Announces Thomas Oakley as New CEO
  
  Description:GAITHERSBURG, Md.--(BUSINESS WIRE)--Bridge Pharmaceuticals, Inc. (Bridge) announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J. Marler as Chief Scientific Officer.
  ...
  "I am proud and excited to lead Bridge as globalization dawns in preclinical drug development," said Mr. Oakley."Just a few years ago, dramatically lowering research costs through globalization was only talked about.Today it is the new reality and an immense opportunity for our company.Bridge is poised for tremendous growth in demand for our services both in the US and China."
  
  Mr. Oakley brings a wealth of experience to Bridge with over 25 years of industry and professional experience.Prior to joining Bridge, Mr. Oakley spent nine years at Covance, Inc. where his assignments included Global Vice President Finance for the Early Development Group, Vice President of the Chemistry Division, and Global Vice President of Business Development.Most recently, Tom was the founder and President of DTO Associates, LLC, a consulting firm that worked with private equity firms and businesses in the areas of strategy, finance and management.

• 
  www.bridgelaboratories.com/readarticle.php?id=1 - [Cached Version]
  Published on: 7/9/2008    Last Visited: 9/21/2008  

  "IP culture has changed significantly in the past few years, and policies are coming into place," D. Thomas Oakley, CEO of Bridge Laboratories, said of an issue that has plagued China from day one.
  
  However, it will not be smooth sailing from here on and the sector should not rest on its laurels.According to Oakley, China is lacking toxicology scientists, which will one day act as a bottleneck to R & D process.In addition, he said that China's R & D boom may mean that the country's abundant animal resources may face a shortage.

• 
  biz.yahoo.com/bw/070730/20070730005152.html?.v=1 - [Cached Version]
  Published on: 7/30/2007    Last Visited: 7/30/2007  

  GAITHERSBURG, Md.--(BUSINESS WIRE)--Bridge Pharmaceuticals, Inc. (Bridge) announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J. Marler as Chief Scientific Officer.
  ...
  "I am proud and excited to lead Bridge as globalization dawns in preclinical drug development," said Mr. Oakley."Just a few years ago, dramatically lowering research costs through globalization was only talked about.Today it is the new reality and an immense opportunity for our company.Bridge is poised for tremendous growth in demand for our services both in the US and China."
  
  Mr. Oakley brings a wealth of experience to Bridge with over 25 years of industry and professional experience.Prior to joining Bridge, Mr. Oakley spent nine years at Covance, Inc. where his assignments included Global Vice President Finance for the Early Development Group, Vice President of the Chemistry Division, and Global Vice President of Business Development.Most recently, Tom was the founder and President of DTO Associates, LLC, a consulting firm that worked with private equity firms and businesses in the areas of strategy, finance and management.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=64593 - [Cached Version]
  Published on: 7/30/2007    Last Visited: 7/30/2007  

  GAITHERSBURG, Md.--(BUSINESS WIRE)--Bridge Pharmaceuticals, Inc. (Bridge) announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J. Marler as Chief Scientific Officer.
  ...
  "I am proud and excited to lead Bridge as globalization dawns in preclinical drug development," said Mr. Oakley."Just a few years ago, dramatically lowering research costs through globalization was only talked about.Today it is the new reality and an immense opportunity for our company.Bridge is poised for tremendous growth in demand for our services both in the US and China."
  
  Mr. Oakley brings a wealth of experience to Bridge with over 25 years of industry and professional experience.Prior to joining Bridge, Mr. Oakley spent nine years at Covance, Inc. where his assignments included Global Vice President Finance for the Early Development Group, Vice President of the Chemistry Division, and Global Vice President of Business Development.Most recently, Tom was the founder and President of DTO Associates, LLC, a consulting firm that worked with private equity firms and businesses in the areas of strategy, finance and management.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=64915 - [Cached Version]
  Published on: 7/31/2007    Last Visited: 7/31/2007  

  July 31, 2007 - Bridge Pharmaceuticals has hired a new CEO, D. Thomas Oakley, replacing Dr. Glenn Rice, who founded Bridge.

• 
  www.dailylead.com/news/aaaa/companyData.jsp?companyId=7 - [Cached Version]
  Published on: 9/5/2007    Last Visited: 11/29/2007  

  Bridge Pharmaceuticals, Inc. (Bridge) announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J. Marler as Chief Scientific Officer.

• 
  www.pharmacychoice.com/News/topic.cfm?TOPIC_ID=2&View=9 - [Cached Version]
  Published on: 9/16/2007    Last Visited: 9/16/2007  

  GAITHERSBURG, Md.-- --July 30, 2007--Bridge Pharmaceuticals, Inc. announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J.

• 
  American Red Cross Badger Chapter - Board of Directors - [Cached Version]
  Published on: 1/1/2004    Last Visited: 8/1/2005  

  D. Thomas OakleyCovance Laboratories, Inc.

• 
  Bridge Pharmaceuticals - [Cached Version]
  Published on: 10/7/2008    Last Visited: 8/11/2007  

  "AAALAC accreditation is what Bridge clients expect," added Bridge CEO Tom Oakley.
  ...
  Gaithersburg, MD - Bridge Pharmaceuticals, Inc. (Bridge) announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J. Marler as Chief Scientific Officer.
  ...
  "I am proud and excited to lead Bridge as globalization dawns in preclinical drug development," said Mr. Oakley."Just a few years ago, dramatically lowering research costs through globalization was only talked about.Today it is the new reality and an immense opportunity for our company.Bridge is poised for tremendous growth in demand for our services both in the US and China."
  
  Mr. Oakley brings a wealth of experience to Bridge with over 25 years of industry and professional experience.Prior to joining Bridge, Mr. Oakley spent nine years at Covance, Inc. where his assignments included Global Vice President Finance for the Early Development Group, Vice President of the Chemistry Division, and Global Vice President of Business Development.Most recently, Tom was the founder and President of DTO Associates, LLC, a consulting firm that worked with private equity firms and businesses in the areas of strategy, finance and management.

Page:  1 2